91804-22-7

Basic information

• Product Name: Methyl 6-cyano-1-naphthoate
• Synonyms: Methyl 6-cyano-1-naphthoate
• CAS NO: 91804-22-7
• Molecular Formula: C13H9NO2
• Molecular Weight: 211.21606
• Mol File: 91804-22-7.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Methyl 6-cyano-1-naphthoate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 6-cyano-1-naphthoate(91804-22-7)
• EPA Substance Registry System: Methyl 6-cyano-1-naphthoate(91804-22-7)

Safety Data

• Hazardous Substances Data: 91804-22-7(Hazardous Substances Data)

Upstream product

• 14221-01-3 tetrakis(triphenylphosphine) palladium⁽⁰⁾ 
• 255050-65-8 6-trifluoromethanesulfonyloxy-naphthalene-1-carboxylic acid methyl ester 
• 91135-41-0 5-Cyan-naphthylamin-⁽²⁾ 
• 91804-23-8 5-cyanonaphthalene-2-carboxylic acid methyl ester 
• 94629-28-4 5-Cyan-naphthoesaeure-⁽²⁾-azid 
• 91493-88-8 5-Cyan-naphthoesaeure-⁽²⁾-hydrazid 
• 91065-16-6 6-bromo-1-cyanonaphthalene 
• 51934-38-4 6-bromo-1-naphthoic acid 
• 67878-76-6 5-bromo-2-naphthalenecarboxylic acid methyl ester 
• 90162-13-3 methyl 6-hydroxy-1-naphthoate 
• 2437-17-4 6-hydroxy-1-naphthoic acid 
• 557-21-1 dicyanozinc 
• 93353-66-3 methyl 6-bromonaphthalene-1-carboxylate 
• 544-92-3 copper(I) cyanide 

Relevant articles and documents

N-SUBSTITUTED NAPHTHALENE CARBOXAMIDES AS NEUROKININ-RECEPTOR ANTAGONISTS

A compound of formula I wherein: R is alkyl; R1 is optionally substituted phenyl 2-oxo-tetrahydro-1(2H)-pyrimidinyl, or 2-oxo-1-piperidinyl; R2 is hydrogen, alkoxy, alkanoyloxy, alkoxycarbonyl, alkanoylamino, acyl, alkyl, carbamoyl, N-alkylcarbamoyl, N,N-dialkylcarbamoyl where the alkyl groups are the same or different, hydroxy, thioacyl, thiocarbamoyl, N-alkylthiocarbamoyl, or N,N-dialkylthiocarbamoyl where the alkyl groups are the same or different. X1 and X2 are independently hydrogen or halo, provided that at least one of X1 or X2 is halo; and R3, R4, R5 and R6 are independently hydrogen, cyano, nitro, trifluoromethoxy, trifluoromethyl, or alkylsulfonyl are antagonists of at least one tachykinin receptor and are useful in the treatment of depression, anxiety, asthma, pain, inflammation, urinary incontinence and other disease conditions. Process for their preparation are described, as are compositions containing them and their use.

Discovery of novel, orally active dual NK1/NK2 antagonists

Exploration of the SAR around selective NK2 antagonists, SR48968 and ZD7944, led to the discovery that naphth-1-amide analogues provide potent dual NK1 and NK2 antagonists. ZD6021 inhibited binding of [3H]-NKA or [3H]-SP to human NK1 and NK2 receptors, with high-affinity (Ki=0.12 and 0.62 nM, respectively). In functional assays ZD6021 had, at 10-7 M, in human pulmonary artery pKB=8.9 and in human bronchus pKB=7.3, for NK1 and NK2, respectively. Oral administration of ZD6021 to guinea pigs dose-dependently attenuated ASMSP induced extravasation of plasma proteins, ED50=0.5 mg/kg, and NK2 mediated bronchoconstriction, ED50=13 mg/kg.